Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imnovid

- PMLiVE

Cancer Research UK and Guardant collaborate to advance cancer detection and treatment

The partnership aims to accelerate the development of cancer drugs and diagnostics

- PMLiVE

The Power of the Partnership: How Patient-Centricity Improves Care

How can the patient’s voice improve care?This was the question Medscape Oncology Clinical Strategist Victoria Harvey-Jones, PhD and Lesley Fallowfield DBE, BSC, DPHIL, FMEDSCI, Professor of Pyscho-Oncology, Sussex Health Outcomes...

Medscape Education Global

- PMLiVE

AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition

The agreement grants the company access to FDA-approved ovarian cancer drug Elahere

- PMLiVE

NHS to offer stem cell transplants to patients living with rare blood disorder

Over 600 adults in the UK are affected by transfusion-dependant thalassaemia

- PMLiVE

New report reveals antibiotic underdosing could be leading cause of AMR in UK

AMR has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies

The regulator will monitor approved BCMA- or CD19-directed autologous CAR-T cell immunotherapies

- PMLiVE

Planting the Seeds for Future Women Leaders in Medicine

What are the qualities needed to be a leader in the medical field of oncology?Of course, you must be a good clinician. But you also have to be wise and...

Medscape Education Global

- PMLiVE

FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours

Approximately 1,650 people in the US are diagnosed with the rare non-cancerous tumours each year

- PMLiVE

GSK shares positive phase 3 results for Blenrep combination in multiple myeloma

Approximately 176,000 new cases of multiple myeloma are diagnosed globally each year

- PMLiVE

Cancer Research UK calls on government to create ten-year cancer plan

The charity estimates that around 20,000 annual cancer deaths in the UK could be prevented by 2040

- PMLiVE

AstraZeneca gains rights to Usynova’s KRAS inhibitor in deal worth almost $420m

There are currently no approved drugs specifically targeting the KRAS G12D mutation

- PMLiVE

Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m

The acquisition marks a significant boost to Boehringer’s immuno-oncology portfolio

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links